PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ijerphMDPI Open Access JournalsMDPI Open Access JournalsThis articleThis JournalInstructions for authorsAdd your e-mail address to receive forthcoming issues of this journal
 
Int J Environ Res Public Health. 2010 April; 7(4): 1448–1466.
Published online 2010 March 30. doi:  10.3390/ijerph7041448
PMCID: PMC2872348

Alcoholism and Alternative Splicing of Candidate Genes

Abstract

Gene expression studies have shown that expression patterns of several genes have changed during the development of alcoholism. Gene expression is regulated not only at the level of transcription but also through alternative splicing of pre-mRNA. In this review, we discuss some of the evidence suggesting that alternative splicing of candidate genes such as DRD2 (encoding dopamine D2 receptor) may form the basis of the mechanisms underlying the pathophysiology of alcoholism. These reports suggest that aberrant expression of splice variants affects alcohol sensitivities, and alcohol consumption also regulates alternative splicing. Thus, investigations of alternative splicing are essential for understanding the molecular events underlying the development of alcoholism.

Keywords: alcoholism, alternative splicing, dopamine, NMDA, GABA, voltage-gated calcium channel, neurexin

1. Introduction

Alternative pre-mRNA splicing makes a large contribution to proteomic diversity. In alternative splicing, various potential splice sites of the pre-mRNA from a single gene are used in various combinations that lead to the translation of several functionally distinct protein isoforms from several different mRNA species. In the brain, the regulation of splice variants modulates protein functions, which can ultimately affect behavior such as alcohol dependence. Alcohol dependence (AD) is a common, chronic and relapsing disorder with an estimated heritability of 40−60% [1]. Family and twin studies have shown that genetic factors contribute to the risk of AD and genetic mapping studies have identified numerous genes associated with this risk [25]. Most of these genes affect ethanol metabolism, ethanol preference, or diverse brain systems, such as the reward system [6,7].

Alterations in expression have been shown to be involved in producing neuroadaptative changes following chronic ethanol consumption [8,9]. A key question in AD is the transition from controlled to compulsive drinking, and development of dependence may be related not only to gene expression modulated through transcriptional regulation but also through alternative splicing of genes, which may produce functionally distinct isoforms.

In this review, we describe several examples of alternative splicing which may affect ethanol preference and consumption. We propose that alternative spliced forms may be important to the development of alcoholism.

2. Ethanol-Associated Genes

2.1. The D2 Dopamine Receptor

The mesolimbic dopamine system plays an important role in the rewarding and reinforcing effect of drugs on the brain [10,11]. It is thought to play a similar role in the rewarding effect of ethanol, as ethanol administration induces the release of dopamine in the nucleus accumbens [12].

Of the five dopamine receptor subtypes, the D2 receptor subtype (DRD2) has been extensively studied in alcoholism [1323]. In rats, a decreased DRD2 density is associated with a preference for ethanol [14], and transient overexpression in the nucleus accumbens attenuated ethanol preference [15]. In humans, positron emission tomography studies have revealed decreased DRD2 availability in the striatum of alcoholics [16,17], and support a hypothesis that a high DRD2 level in the striatum is a protective factor against alcoholism [18]. Moreover, polymorphisms of the DRD2 gene are linked with an altered risk of alcoholism [1923].

Alternative splicing generates two DRD2 isoforms, D2S and D2L. These isoforms differ in that D2L has a sixth exon, which encodes its third cytoplasmic region [24]. Although the two isoforms are co-expressed, D2S is preferentially expressed in dopaminergic neurons in presynaptic regions, such as the substantia nigra and the hypothalamus, and D2L predominates in postsynaptic regions, such as the striatum and the pituitary gland [2527]. In recombinant cell lines and mouse brains, D2L has a lower affinity for dopamine than D2S [24,28,29]. DRD2 is coupled with Gαi, an adenylyl cyclase-inhibiting G protein, and because Gαi binding is mediated by the third cytoplasmic loop of DRD2, D2S and D2L have different specificities for the subtypes of Gαi [3032].

The D2S and D2L isoforms also differ in their effects on downstream protein phosphorylation. D2S has been suggested to decrease the phosphorylation of tyrosine hydroxylase, and D2L has been suggested to increase the dopamine D1 receptor (DRD1)-induced phosphorylation of DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of 32 kDa) [33]. In addition, D2S and D2L have been reported to differ in the levels of their accumulation in the endoplasmic reticulum (ER) [34] and in the regulation of their sequestration by G protein-coupled receptor kinases and β-arrestins [35]. Furthermore, although both D2L and D2S participate in the presynaptic inhibition of γ-aminobutyric acid (GABA) release in the striatum, the presynaptic inhibition of glutamate release is preferentially modulated by D2S [36]. D2L-deficient mice showed distinct pharmacological behavior from DRD2-deficient mice and wild-type mice, suggesting that the D2L splice variant has different functions from D2S in vivo [27,29,37,38].

Ethanol affects the alternative splicing of DRD2 pre-mRNA [39]. Ethanol administration to rats has been reported to increase the D2L/D2S receptor ratio in the pituitary gland, and this effect was reproduced in primary cultures of pituitary cells treated with ethanol. We separately confirmed this effect of ethanol on DRD2 splicing in the human neuroblastoma cell line SH-SY5Y (unpublished data). In pituitary cells, ethanol not only alters DRD2 splicing, but also diminishes the inhibition of prolactin secretion by the DRD2-specific analog bromocriptine [39]. These facts suggest that ethanol suppresses dopamine-induced responses by altering DRD2 splicing. Allelic expression analysis in human postmortem brain tissues and functional magnetic resonance imaging measurements in healthy humans have shown that T carriers of single-nucleotide polymorphisms (SNPs) rs2283265 and rs1076560, both of which flank DRD2 exon 6, express relatively fewer D2S receptors and exhibit worse performance during working tasks [40]. We have demonstrated that T carriers of SNP rs1076560 have a higher alcoholism risk [22].

These findings suggest that individuals possessing fewer D2S receptors, such as T carriers, have less intense responses to dopamine (like ethanol-preferring rats) and therefore prefer to drink alcohol. Furthermore, this tendency is enhanced through a positive feedback loop in which ethanol administration decreases the number of D2S receptors.

2.2. The N-Methyl-d-aspartate (NMDA) Receptor NR1 Subunit

The NMDA (N-methyl-D-aspartate) receptor, an ionotropic glutamate receptor in the central nervous system, is a pivotal target of ethanol [41]. Ethanol attenuates NMDA receptor function in a dose-related fashion in vitro [42,43]. The NMDA receptor is a heteromeric protein composed of at least one NR1 subunit and at least one NR2 subunit. Ethanol appears to bind to the NR1 subunit in a hydrophobic pocket associated with the third transmembrane domain [44]. Ligand binding to the NMDA receptor is up-regulated in rodents chronically treated with ethanol [43,4548] and in postmortem cortical tissue from alcoholic patients [49,50]. This up-regulation of the NMDA receptor reduces ethanol sensitivity and therefore contributes to ethanol tolerance [51].

The NMDA receptor is a cation channel with high Ca2+ permeability. The NR1 subunit is essential for receptor–channel function, and the NR2 subunit modulates the properties of the channel [52]. The recently identified NMDA subunit NR3 decreases NMDA-induced current and Ca2+ permeability [53,54].

The NR1 subunit has eight isoforms generated by alternative splicing of exons 5, 21, and 22. The NR1-a variant lacks exon 5, which encodes the N1 splice cassette that lies in the extracellular N-terminal domain of the NR1 subunit, and NR1-b includes exon 5. Exons 21 and 22 encode the C-terminal splice cassettes C1 and C2, respectively, and are part of the intracellular domain of the NR1 subunit. NR1 splice variants lacking exon 22 contain a C2’ cassette as an additional cassette at their C-terminal end (see Figure 1 in reference [55]). These splice variants vary considerably in their properties and are differentially localized in adult and developing animals [56,57].

These alternative cassettes modulate the properties of the NMDA receptor. The presence of the N1 cassette, which forms a surface loop with structural similarities to polyamines, decreases the affinities of the receptor for NMDA and glutamate [58]. It potentiates the receptor function by relieving the tonic proton inhibition [59] and voltage-independent zinc inhibition [60]. It also accelerates the deactivation time course of NMDA responses when NR1 is co-expressed with the NR2B (but not NR2A) subunit [61,62]. The first C1 cassette includes a calmodulin-binding site, and binding of calmodulin to NR1 inhibits NMDA channel activity [6365]. Although the C1 cassette also has protein kinase C (PKC) phosphorylation sites, and phosphorylation affects the subcellular distribution of NR1 [66], PKC potentiation of the NMDA receptor probably does not occur through direct phosphorylation of the receptor but, rather, through phosphorylation of receptor-associated proteins [67,68].

Interestingly, the NR1 isoforms have differential sensitivities to ethanol-induced inhibition. When expressed singly in Xenopus oocytes, the sensitivity of the NR1-1b, NR1-2b, NR1-1a, and NR1-2a isoforms to ethanol follows the order NR1-1b > NR1-2b > NR1-1a > NR1-2a [69]. In contrast, when all eight NR1 isoforms are co-expressed in various combinations with one of the four NR2 subtypes in human embryonic kidney 293 cells, the sensitivity depends on the combination. For example, the NR1-3b/NR2C, NR1-3b/NR2D, and NR1-4b/NR2C pairs are most weakly inhibited by ethanol (approximately 15% inhibition), and the NR1-2b/NR2C pair is most strongly inhibited by ethanol (>50% inhibition) [70].

Several reports have described the modulation of expression of specific NR1 isoforms by ethanol [54,57,7177]. Some of the reported findings appear to be inconsistent. For example, although mRNA ratio of NR1 splice variants containing exon 5 to those lacking exon 5 (+E5/–E5) decreases in the cortex of rats exposed to ethanol vapor [72] and in mouse fetal cortical neurons treated with ethanol [73], it increases in the striatum of rats chronically treated with ethanol solution [77]. Raeder et al. [77] postulated that this inconsistency arises from differences in the dose, duration of consumption, and route of administration of alcohol. In addition, the effects of ethanol on the expression of NR1 isoforms might differ in each brain region.

Thus, despite this inconsistency, ethanol consumption may increase NR1 isoforms that are weakly inhibited by ethanol. Together with up-regulation of the NMDA receptors [37,3944], this regulation of splice variants should contribute to the reduction of ethanol sensitivity and the induction of ethanol tolerance.

2.3. The GABAA Receptor γ2 Subunit

The ionotropic GABAA receptor, a GABA-gated chloride channel receptor, is involved in the diverse effects of ethanol on the central nervous system [78]. The ionotropic GABAA receptor and the metabotropic GABAB receptor mediate the inhibition of neuronal excitability by GABA. The majority of fast synaptic inhibition is mediated through the GABAA receptor. Acute ethanol administration enhances GABAA receptor activity at intoxicating concentrations, whereas chronic ethanol administration decreases GABAergic function [7981]. Together with up-regulation of the NMDA receptor, this down-regulation of the GABAA receptor contributes to ethanol tolerance, dependence, and withdrawal hyperexcitability. Ethanol directly binds to a pocket located between transmembrane domains of the GABAA receptor, inducing conformational changes [8284]. Dopaminergic neurons in the midbrain are activated not only directly through ethanol exposure, but also indirectly through the down-regulation of GABAergic inhibitory transmission to these neurons [8587].

The GABAA receptor is a heteromer of five subunits. Almost all GABAA receptors consist of two α, two β, and one γ subunit; the most frequent combinations are α1β2γ2, α2β3γ2, and α3β3γ2, which comprise approximately 60, 15, and 10% of GABAA receptor proteins, respectively [88]. Genes for these subunits form clusters on several chromosomal regions; 4p13–q11 (α2, α4, β1, γ1), 5q34–q35 (α1, α6, β2, γ2), 15q11–q13 (α5, β3, γ3), and Xq28 (α3, β4, epsilon1). Mice with knockouts of these genes generally do not exhibit alcohol-preferring behaviors [78]. Moreover, agonists of the GABAA receptor enhance alcohol-drinking behavior, and antagonists inhibit it [8991]. These results illustrate the importance of the GABAA receptor in alcohol consumption.

The GABAA receptor α2 subunit has four major isoforms differing in their combinations of two alternative exons (exon 1A versus exon 1B and exon 9A versus exon 10) and two minor isoforms lacking exon 4 or exon 8 [92]. Two haplotypes of the α2 subunit gene (GABRA2) have been reported to be significant risk factors for AD, although this conclusion is inconsistent with several other studies [93]. Some non-coding variations in the GABRA2 gene have been found to be associated with AD [94]. Because several SNPs are located in exon 8, exon 9, or in the introns flanking these exons, one can speculate that these SNPs affect the alternative splicing of these exons.

The γ2 subunit has two splice variants, one long (γ2L) and one short (γ2S). The γ2L variant differs from the γ2S variant in that it has an eight-amino-acid insert in the intracellular loop between transmembrane domains three and four. Intriguingly, in rats, chronic intermittent ethanol administration decreases the hippocampal ratio of γ2L/γ2S [95]. The γ2L insert modulates GABAA receptor function; it contains a serine residue that is phosphorylated by PKC, reducing the amplitudes of GABA-activated currents [96]. In addition, when γ2L is co-expressed with α and β subunits in Xenopus oocytes, only the γ2L subunit is sensitive to the reinforcing effect of ethanol [97]. It also exhibits accelerated deactivation in human embryonic kidney 293 cells [98]. Knockout mice lacking this insert (γ2L-KO) appear to be unaffected in their electrophysiological and behavioral response to ethanol [99], contrary to the different effects of the isoforms mentioned above. On the other hand, γ2L accumulates at inhibitory postsynaptic sites more effectively than γ2S, and this accumulation is facilitated by PKC phosphorylation of the γ2L insert [100]. Meier and Grantyn argue that γ2S functions sufficiently in γ2L-KO mice only because it does not have to compete with γ2L for gephyrin binding sites and that it actually differs from γ2L in its properties [100]. Moreover, expression of the γ2L and α1 subunits increases during development; they are the predominant isoforms in mature GABAergic synapses [101]. Thus, a reduced γ2L/γ2S ratio probably interferes with the maturation of inhibitory synapses and may indicate a higher risk of alcoholism.

2.4. N-Type and L-type Voltage-gated Ca2+ Channels

Opening of voltage-gated Ca2+ channels depends on the membrane potential. The resulting influx of Ca2+ into the cell triggers various events including neurotransmitter release. Ca2+ channels are composed of at least three subunits (α1, α2δ, and β). The α1 subunit is critical for Ca2+ channel functions, and its various subtypes confer functional diversity.

The N-type Ca2+ channel is involved in the molecular and behavioral effects of ethanol. Acute ethanol exposure inhibits the activity of the N-type channel in PC12 cells [102], whereas chronic ethanol exposure increases the density of N-type channels and therefore increases depolarization-evoked Ca2+ influx [103]. In addition, mice lacking N-type channels exhibit reduced voluntary ethanol consumption and preference [104]. Treatment with the mixed N-type and T-type channel antagonist NP078585 has a phenotypic effect similar to that of ethanol [105].

The α1 subunit of the N-type channel is α12.2, which has three alternative exons (exon 18a, exon 24a, and exon 31a). The splice variants of these exons exhibit functionally diverse Ca2+ signaling in neurons. Exon 31a encodes two amino acids in the IVS3-IVS4 linker, altering the rate of channel opening and the voltage dependence of channel activation [106,107]. Chronic ethanol exposure decreases expression of the variant lacking exon 31a and increases the N-type current [108], suggesting that ethanol facilitates the functions of N-type Ca2+ channels by altering the composition of splice variants.

The L-type channel is also involved in ethanol consumption. Acute ethanol exposure inhibits the L-type channel, whereas chronic ethanol exposure induces a rise in the voltage-gated Ca2+ current, an effect thought to reflect up-regulation of the L-type channel [109,110]. In addition, L-type channel antagonists decrease ethanol withdrawal symptoms and ethanol self-administration in rodents [111,112].

The α1C subunit of the L-type channel has two splice variants, α1C-1 and α1C-2. These variants differ in that α1C-1 has three additional amino acid residues between domains II and III and 28 additional residues in the S3 segment in domain IV. They are differentially expressed in rat brain [113], but little is known about their differences in function. Ethanol treatment in PC12 cells has been reported to increase the level of α1C protein in a PKCδ activity-dependent manner, whereas it increases the mRNA level of α1C-1, but not α1C-2, independent of PKCδ [114]. These results indicate that ethanol up-regulates the L-type channel by increasing expression of the α1C-1 splice variant, in addition to PKCδ-dependent and post-transcriptional regulation.

Ethanol consumption appears to alter the ratios of splice variants, thereby up-regulating N- and L-type calcium channels. This up-regulation appears to induce the neuronal hyperexcitability observed during ethanol withdrawal.

2.5. Large-Conductance Calcium- and Voltage-Activated Potassium Channels (BK)

BK channels are large-conductance calcium- and voltage-activated potassium channels. K+ currents carried by BK channels participate in repolarization and hyperpolarization of action potentials, setting neuron firing properties [115]. BK channels consist of α core and β auxiliary subunits. The α core subunit forms a ion-selective pore, a voltage-sensing module, and a Ca2+-sensing module important for activation of the channel [116].

The activity of BK channels is modified by clinical doses of ethanol. Ethanol exposure potentiates BK activity in cell-free membranes and a cultured explant from rat posterior pituitary gland [117,118]. And BK channels in pituitary tumor (GH3) cells are also activated by ethanol [119]. This potentiation of BK channels in pituitary cells may contribute to the regulation of hormone secretion. Additionally, in a subgroup of primary sensory neurons in rat dorsal root ganglia, the BK potentiation by ethanol reduces neuronal excitability, and therefore, may underlie analgesic action in the peripheral nervous system [120]. Conversely, BK channels in arterial smooth muscle are inhibited by ethanol [121,122]. This ethanol-induced inhibition of BK channels may be a mechanism underlying contraction of vascular smooth muscle. And protracted ethanol exposure decreases ethanol sensitivity and the number of functional BK channels by cellular internalization, resulting in the tolerance to ethanol [118,123].

The response and adaptation of BK channels to ethanol is modulated by the phosphorylation state of the channel protein [124], membrane lipid environment [125127], and the composition of β auxiliary subunits [123,128]. Moreover, altered expression of splice variants encoding the β core subunit is an underlying mechanism for the ethanol tolerance of BK channels [129]. Pietrzykowski and colleagues reported that, in the supraoptic nucleus and the striatal neurons, brief ethanol exposure decreased the splice variants of BK channels that are highly sensitive to ethanol. This down-regulation of alternatively spliced BK variants is caused by selective degradation of pre-existing mRNA, not by the regulation of alternative splicing. Ethanol exposure increases the expression of a miRNA (miR-9) that binds to 3’UTR sequence specific to the ethanol-sensitive splice variants, and therefore, enhances the degradation of these splice variants. And this molecular tolerance of BK channels to ethanol may contribute to the behavioral adaptation to ethanol.

2.6. Neurexin-3

In addition to modulating neurotransmitter receptors and ion channels, ethanol has been reported to inhibit cell–cell adhesion [130] and neurite outgrowth mediated by the L1 cell adhesion molecule (L1CAM) [131]. Ethanol directly binds to L1CAM at a critical domain interface [132] and disrupts its signaling cascade [133], suggesting that cell adhesion molecules are targets of ethanol.

The neuronal proteins known as neurexins function as cell adhesion molecules at presynaptic sites with extracellular binding partners, such as neuroligins, dystroglycan, and neurexophilins [134]. Neurexins modulate postsynaptic differentiation and receptor clustering [135] and perform an essential role in Ca2+-triggered neurotransmitter release by modulating voltage-dependent Ca2+ channels [136138]. The gene for one of the neurexin family proteins, neurexin-3, is associated with nicotine dependence [139,140], opioid dependence [141], and poly-substance abuse [142], and cocaine exposure increases neurexin-3 expression in the globus pallidus of mice [143]. Moreover, neurexin-3 is expressed in neurons projecting to brain regions involved in addictive behaviors, such as the nucleus accumbens and the striatum [144] (http://www.brain-map.org/).

Neurexin genes have two distinct promoters from which longer forms (α-neurexins) and shorter forms (β-neurexins) are transcribed. In addition, α-neurexins have five alternative splice sites (splice sites 1–5) and β-neurexins have two (splice sites 4 and 5). In this way, an enormously diverse range of neurexin proteins are generated from each neurexin gene, and this diversity modulates synaptic functions [145]. For example, alternative splicing at splice site 4 modulates the binding affinity and specificity for neuroligins [146].

The splice site producing the greatest variety of proteins is splice site 5 of neurexin-3, which includes three exons (exons 22, 23, and 24). Exon 23 is very important because its inclusion confers solubility on neurexin-3 isoforms, and the transcripts lacking this exon encode transmembrane isoforms. SNP rs8019381, which is in the intronic sequence adjacent to the donor splice site of exon 23, is strongly associated with alcohol dependence and forms a haplotype block with rs760288 and rs2293847 [147]. Furthermore, T allele carriers of rs8019381 express fewer soluble isoforms lacking exon 23. Therefore, this polymorphism might increase the risk of alcoholism by affecting the alternative splicing of exon 23 and modulating the synaptic function of neurexin-3.

3. Concluding Remarks

Ethanol consumption can modulate not only the level of total transcripts of multiple genes, but also the ratio of their splice variants. Because splice variants have different functions, the altered expression of splice variants can ultimately affect behavior such as alcohol dependence. Indeed, as mentioned in this review, splice variants of DRD2 may affect ethanol preference by modulating dopamine sensitivity. And lower ethanol-sensitive splice variants of NMDA receptor, GABAA receptor, and ion channels contribute to ethanol tolerance. In addition, splice variants of GABAA receptor, voltage-gated Ca2+ channels, and neurexin-3 possibly contribute to withdrawal symptoms by inducing neuronal hyperexcitability. Furthermore, these propensities for ethanol can enhance ethanol consumption in turn. We propose this positive feedback as a mechanism underlying the development of alcoholism. Moreover, among candidate genes mentioned above, DRD2 and neurexin-3 have polymorphisms that are associated with both the risk of alcoholism and the expression ratio of splice variants. Therefore, polymorphisms without amino acid alteration in multiple candidate genes probably increase the risk of alcoholism by modulating the expression of alternatively spliced variants.

Many intriguing questions remain to be answered, such as how ethanol affects the splicing machinery. The oxidative stress induced in ethanol metabolism might be a factor; ethanol consumption results in the production of reactive oxygen species by the mitochondrial electron transport chain, cytochrome P450 2E1, and activated phagocytes [148], and chemical stresses are known to affect the splicing of specific pre-mRNAs [149].

Another question concerns the genome-wide ethanol-associated changes in alternative splicing. Ethanol-associated splice variants have thus far been investigated only for specific genes, not for the entire genome. For a genome-wide study, next generation sequencing is a useful screening tool for detecting both the altered expression of splice variants and alcoholism-associated polymorphisms. And a custom microarray such as the one generated by Johnson and colleagues [150] is also useful for studies of alternative splicing in multifactorial disorders including alcoholism.

References and Notes

1. McGue M. Phenotyping alcoholism. Alcohol Clin. Exp. Res. 1999;23:757–758. [PubMed]
2. Crabbe JC, Phillips TJ, Harris RA, Arends MA, Koob GF. Alcohol-related genes: contributions from studies with genetically engineered mice. Addict. Biol. 2006;11:195–269. [PubMed]
3. Mayfield RD, Harris RA, Schuckit MA. Genetic factors influencing alcohol dependence. Br. J. Pharmacol. 2008;154:275–287. [PMC free article] [PubMed]
4. Gelernter J, Kranzler HR. Genetics of alcohol dependence. Hum. Genet. 2009;126:91–99. [PubMed]
5. Kalsi G, Prescott CA, Kendler KS, Riley BP. Unraveling the molecular mechanisms of alcohol dependence. Trends Genet. 2009;25:49–55. [PubMed]
6. Mulligan MK, Ponomarev I, Hitzemann R, Belknap JK, Tabakoff B, Harris RA, Crabbe JC, Blednov YA, Grahame NJ, Phillips TJ, Finn DA, Hoffman PL, Iyer VR, Koob GF, Bergeson SE. Toward understanding the genetics of alcohol drinking through transcriptome meta-analysis. Proc. Natl. Acad. Sci. U.S.A. 2006;103:6368–6373. [PubMed]
7. Hodgkinson CA, Yuan Q, Xu K, Shen PH, Heinz E, Lobos EA, Binder EB, Cubells J, Ehlers CL, Gelernter J, Mann J, Riley B, Roy A, Tabakoff B, Todd RD, Zhou Z, Goldman D. Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. Alcohol Alcohol. 2008;43:505–515. [PMC free article] [PubMed]
8. Liu J, Lewohl JM, Harris RA, Iyer VR, Dodd PR, Randall PK, Mayfield RD. Patterns of gene expression in the frontal cortex discriminate alcoholic from nonalcoholic individuals. Neuropsychopharmacology. 2006;31:1574–1582. [PubMed]
9. Kerns RT, Ravindranathan A, Hassan S, Cage MP, York T, Sikela JM, Williams RW, Miles MF. Ethanol-responsive brain region expression networks: implications for behavioral responses to acute ethanol in DBA/2J versus C57BL/6J mice. J. Neurosci. 2005;25:2255–2266. [PubMed]
10. Tupala E, Tiihonen J. Dopamine and alcoholism: neurobiological basis of ethanol abuse. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2004;28:1221–1247. [PubMed]
11. Di Chiara G, Bassareo V. Reward system and addiction: what dopamine does and doesn't do. Curr. Opin. Pharmacol. 2007;7:69–76. [PubMed]
12. Yim HJ, Schallert T, Randall PK, Gonzales RA. Comparison of local and systemic ethanol effects on extracellular dopamine concentration in rat nucleus accumbens by microdialysis. Alcohol Clin. Exp. Res. 1998;22:367–374. [PubMed]
13. Tupala E, Tiihonen J. Dopamine and alcoholism: neurobiological basis of ethanol abuse. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2004;28:1221–1247. [PubMed]
14. McBride WJ, Chernet E, Dyr W, Lumeng L, Li TK. Densities of dopamine D2 receptors are reduced in CNS regions of alcohol-preferring P rats. Alcohol. 1993;10:387–390. [PubMed]
15. Thanos PK, Taintor NB, Rivera SN, Umegaki H, Ikari H, Roth G, Ingram DK, Hitzemann R, Fowler JS, Gatley SJ, Wang GJ, Volkow ND. DRD2 gene transfer into the nucleus accumbens core of the alcohol preferring and nonpreferring rats attenuates alcohol drinking. Alcohol Clin. Exp. Res. 2004;28:720–728. [PubMed]
16. Hietala J, West C, Syvalahti E, Nagren K, Lehikoinen P, Sonninen P, Ruotsalainen U. Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence. Psychopharmacology (Berl) 1994;116:285–290. [PubMed]
17. Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemann R, Ding YS, Pappas N, Shea C, Piscani K. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin. Exp. Res. 1996;20:1594–1598. [PubMed]
18. Volkow ND, Wang GJ, Begleiter H, Porjesz B, Fowler JS, Telang F, Wong C, Ma Y, Logan J, Goldstein R, Alexoff D, Thanos PK. High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors. Arch. Gen. Psychiatry. 2006;63:999–1008. [PubMed]
19. Blum K, Noble EP, Sheridan PJ, Montgomery A, Ritchie T, Jagadeeswaran P, Nogami H, Briggs AH, Cohn JB. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA. 1990;263:2055–2060. [PubMed]
20. Parsian A, Todd RD, Devor EJ, O'Malley KL, Suarez BK, Reich T, Cloninger CR. Alcoholism and alleles of the human D2 dopamine receptor locus. Studies of association and linkage. Arch. Gen. Psychiatry. 1991;48:655–663. [PubMed]
21. Noble EP. The D2 dopamine receptor gene: a review of association studies in alcoholism and phenotypes. Alcohol. 1998;16:33–45. [PubMed]
22. Sasabe T, Furukawa A, Matsusita S, Higuchi S, Ishiura S. Association analysis of the dopamine receptor D2 (DRD2) SNP rs1076560 in alcoholic patients. Neurosci. Lett. 2007;412:139–142. [PubMed]
23. Smith L, Watson M, Gates S, Ball D, Foxcroft D. Meta-analysis of the association of the Taq1A polymorphism with the risk of alcohol dependency: a HuGE gene-disease association review. Am. J. Epidemiol. 2008;167:125–138. [PubMed]
24. Dal Toso R, Sommer B, Ewert M, Herb A, Pritchett DB, Bach A, Shivers BD, Seeburg PH. The dopamine D2 receptor: two molecular forms generated by alternative splicing. EMBO J. 1989;8:4025–4034. [PubMed]
25. Neve KA, Neve RL, Fidel S, Janowsky A, Higgins GA. Increased abundance of alternatively spliced forms of D2 dopamine receptor mRNA after denervation. Proc. Natl. Acad. Sci. U.S.A. 1991;88:2802–2806. [PubMed]
26. Khan ZU, Mrzljak L, Gutierrez A, de la Calle A, Goldman-Rakic PS. Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc. Natl. Acad. Sci. U.S.A. 1998;95:7731–7736. [PubMed]
27. Usiello A, Baik JH, Roug Pont F, Picetti R, Dierich A, LeMeur M, Piazza PV, Borrelli E. Distinct functions of the two isoforms of dopamine D2 receptors. Nature. 2000;408:199–203. [PubMed]
28. Vile JM, D’Souza UM, Strange PG. [3H]nemonapride and [3H]spiperone label equivalent numbers of D2 and D3 dopamine receptors in a range of tissues and under different conditions. J. Neurochem. 1995;64:940–943. [PubMed]
29. Wang Y, Xu R, Sasaoka T, Tonegawa S, Kung MP, Sankoorikal EB. Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. J. Neurosci. 2000;20:8305–8314. [PubMed]
30. Senogles SE. The D2 dopamine receptor isoforms signal through distinct Gi alpha proteins to inhibit adenylyl cyclase. A study with site-directed mutant Gi alpha proteins. J. Biol. Chem. 1994;269:23120–23127. [PubMed]
31. Senogles SE, Heimert TL, Odife ER, Quasney MW. A region of the third intracellular loop of the short form of the D2 dopamine receptor dictates Gi coupling specificity. J. Biol. Chem. 2004;279:1601–1606. [PubMed]
32. Guiramand J, Montmayeur JP, Ceraline J, Bhatia M, Borrelli E. Alternative splicing of the dopamine D2 receptor directs specificity of coupling to G-proteins. J. Biol. Chem. 1995;270:7354–7358. [PubMed]
33. Lindgren N, Usiello A, Goiny M, Haycock J, Erbs E, Greengard P, Hokfelt T, Borrelli E, Fisone G. Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc. Natl. Acad. Sci. U.S.A. 2003;100:4305–4309. [PubMed]
34. Prou D, Gu WJ, Le Crom S, Vincent JD, Salamero J, Vernier P. Intracellular retention of the two isoforms of the D(2) dopamine receptor promotes endoplasmic reticulum disruption. J. Cell Sci. 2001;114:3517–3527. [PubMed]
35. Cho DI, Beom S, Van Tol HH, Caron MG, Kim KM. Characterization of the desensitization properties of five dopamine receptor subtypes and alternatively spliced variants of dopamine D2 and D4 receptors. Biochem. Biophys. Res. Commun. 2006;350:634–640. [PubMed]
36. Centonze D, Usiello A, Gubellini P, Pisani A, Borrelli E, Bernardi G, Calabresi P. Dopamine D2 receptor-mediated inhibition of dopaminergic neurons in mice lacking D2L receptors. Neuropsychopharmacology. 2002;27:723–726. [PubMed]
37. Xu R, Hranilovic D, Fetsko LA, Bucan M, Wang Y. Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice. Mol. Psychiatry. 2002;7:1075–1082. [PubMed]
38. Hranilovic D, Bucan M, Wang Y. Emotional response in dopamine D2L receptor-deficient mice. Behav. Brain Res. 2008;195:246–250. [PMC free article] [PubMed]
39. Oomizu S, Boyadjieva N, Sarkar DK. Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor messenger RNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland. Alcohol Clin. Exp. Res. 2003;27:975–980. [PMC free article] [PubMed]
40. Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R, Lee ML, Xiao T, Papp A, Wang D, Sadee W. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc. Natl. Acad. Sci. U.S.A. 2007;104:20552–20557. [PubMed]
41. Davis KM, Wu JY. Role of glutamatergic and GABAergic systems in alcoholism. J. Biomed. Sci. 2001;8:7–19. [PubMed]
42. Grant KA, Lovinger DM. Cellular and behavioral neurobiology of alcohol: receptor-mediated neuronal processes. Clin. Neurosci. 1995;3:155–164. [PubMed]
43. Wirkner K, Poelchen W, Koles L, Mlberg K, Scheibler P, Allgaier C, Illes P. Ethanol-induced inhibition of NMDA receptor channels. Neurochem. Int. 1999;35:153–162. [PubMed]
44. Ronald KM, Mirshahi T, Woodward JJ. Ethanol inhibition of N-methyl-D-aspartate receptors is reduced by site-directed mutagenesis of a transmembrane domain phenylalanine residue. J. Biol. Chem. 2001;276:44729–44735. [PubMed]
45. Follesa P, Ticku MK. NMDA receptor upregulation: molecular studies in cultured mouse cortical neurons after chronic antagonist exposure. J. Neurosci. 1996;16:2172–2178. [PubMed]
46. Hu XJ, Follesa P, Ticku MK. Chronic ethanol treatment produces a selective upregulation of the NMDA receptor subunit gene expression in mammalian cultured cortical neurons. Brain Res. Mol. Brain Res. 1996;36:211–218. [PubMed]
47. Hu XJ, Ticku MK. Functional characterization of a kindling-like model of ethanol withdrawal in cortical cultured neurons after chronic intermittent ethanol exposure. Brain Res. 1997;767:228–234. [PubMed]
48. Trevisan L, Fitzgerald LW, Brose N, Gasic GP, Heinemann SF, Duman RS, Nestler EJ. Chronic ingestion of ethanol up-regulates NMDAR1 receptor subunit immunoreactivity in rat hippocampus. J. Neurochem. 1994;62:1635–1638. [PubMed]
49. Freund G, Anderson KJ. Glutamate receptors in the frontal cortex of alcoholics. Alcohol Clin. Exp. Res. 1996;20:1165–1172. [PubMed]
50. Freund G, Anderson KJ. Glutamate receptors in the cingulate cortex, hippocampus, and cerebellar vermis of alcoholics. Alcohol Clin. Exp. Res. 1999;23:1–6. [PubMed]
51. Krystal JH, Petrakis IL, Mason G, Trevisan L, D’Souza DC. N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol. Ther. 2003;99:79–94. [PubMed]
52. Dunah AW, Yasuda RP, Luo J, Wang Y, Prybylowski KL, Wolfe BB. Biochemical studies of the structure and function of the N-methyl-D-aspartate subtype of glutamate receptors. Mol. Neurobiol. 1999;19:151–179. [PubMed]
53. Ciabarra AM, Sullivan JM, Gahn LG, Pecht G, Heinemann S, Sevarino KA. Cloning and characterization of chi-1: a developmentally regulated member of a novel class of the ionotropic glutamate receptor family. J. Neurosci. 1995;15:6498–6508. [PubMed]
54. Nishi M, Hinds H, Lu HP, Kawata M, Hayashi Y. Motoneuron-specific expression of NR3B, a novel NMDA-type glutamate receptor subunit that works in a dominant-negative manner. J Neurosci. 2001;21:RC185. [PubMed]
55. Standley S, Roche KW, McCallum J, Sans N, Wenthold RJ. PDZ domain suppression of an ER retention signal in NMDA receptor NR1 splice variants. Neuron. 2000;28:887–898. [PubMed]
56. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol. Rev. 1999;51:7–61. [PubMed]
57. Laurie DJ, Putzke J, Zieglgansberger W, Seeburg PH, Tolle TR. The distribution of splice variants of the NMDAR1 subunit mRNA in adult rat brain. Brain Res. Mol. Brain Res. 1995;32:94–108. [PubMed]
58. Durand GM, Gregor P, Zheng X, Bennett MV, Uhl GR, Zukin RS. Cloning of an apparent splice variant of the rat N-methyl-D-aspartate receptor NMDAR1 with altered sensitivity to polyamines and activators of protein kinase C. Proc. Natl. Acad. Sci. U.S.A. 1992;89:9359–9363. [PubMed]
59. Traynelis SF, Hartley M, Heinemann SF. Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines. Science. 1995;268:873–876. [PubMed]
60. Traynelis SF, Burgess MF, Zheng F, Lyuboslavsky P, Powers JL. Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit. J. Neurosci. 1998;18:6163–6175. [PubMed]
61. Vicini S, Wang JF, Li JH, Zhu WJ, Wang YH, Luo JH, Wolfe BB, Grayson DR. Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors. J. Neurophysiol. 1998;79:555–566. [PubMed]
62. Rumbaugh G, Prybylowski K, Wang JF, Vicini S. Exon 5 and spermine regulate deactivation of NMDA receptor subtypes. J. Neurophysiol. 2000;83:1300–1306. [PubMed]
63. Ehlers MD, Zhang S, Bernhadt JP, Huganir RL. Inactivation of NMDA receptors by direct interaction of calmodulin with the NR1 subunit. Cell. 1996;84:745–755. [PubMed]
64. Rycroft BK, Gibb AJ. Regulation of single NMDA receptor channel activity by alpha-actinin and calmodulin in rat hippocampal granule cells. J Physiol. 2004;557:795–808. [PubMed]
65. Ataman ZA, Gakhar L, Sorensen BR, Hell JW, Shea MA. The NMDA receptor NR1 C1 region bound to calmodulin: structural insights into functional differences between homologous domains. Structure. 2007;15:1603–1617. [PMC free article] [PubMed]
66. Ehlers MD, Tingley WG, Huganir RL. Regulated subcellular distribution of the NR1 subunit of the NMDA receptor. Science. 1995;269:1734–1737. [PubMed]
67. Zheng X, Zhang L, Wang AP, Bennett MV, Zukin RS. Protein kinase C potentiation of N-methyl-D-aspartate receptor activity is not mediated by phosphorylation of N-methyl-D-aspartate receptor subunits. Proc. Natl. Acad. Sci. U.S.A. 1999;96:15262–15267. [PubMed]
68. Lan JY, Skeberdis VA, Jover T, Grooms SY, Lin Y, Araneda RC, Zheng X, Bennett MV, Zukin RS. Protein kinase C modulates NMDA receptor trafficking and gating. Nat. Neurosci. 2001;4:382–390. [PubMed]
69. Koltchine V, Anantharam V, Wilson A, Bayley H, Treistman SN. Homomeric assemblies of NMDAR1 splice variants are sensitive to ethanol. Neurosci. Lett. 1993;152:13–16. [PubMed]
70. Jin C, Woodward JJ. Effects of 8 different NR1 splice variants on the ethanol inhibition of recombinant NMDA receptors. Alcohol Clin. Exp. Res. 2006;30:673–679. [PubMed]
71. Winkler A, Mahal B, Kiianmaa K, Zieglgansberger W, Spanagel R. Effects of chronic alcohol consumption on the expression of different NR1 splice variants in the brain of AA and ANA lines of rats. Brain. Res. Mol. Brain Res. 1999;72:166–175. [PubMed]
72. Hardy PA, Chen W, Wilce PA. Chronic ethanol exposure and withdrawal influence NMDA receptor subunit and splice variant mRNA expression in the rat cerebral cortex. Brain Res. 1999;819:33–39. [PubMed]
73. Kumari M. Differential effects of chronic ethanol treatment on N-methyl-D-aspartate R1 splice variants in fetal cortical neurons. J. Biol. Chem. 2001;276:29764–29771. [PubMed]
74. Nagy J, Kolok S, Dezso P, Boros A, Szombathelyi Z. Differential alterations in the expression of NMDA receptor subunits following chronic ethanol treatment in primary cultures of rat cortical and hippocampal neurones. Neurochem. Int. 2003;42:35–43. [PubMed]
75. Honse Y, Nixon KM, Browning MD, Leslie SW. Cell surface expression of NR1 splice variants and NR2 subunits is modified by prenatal ethanol exposure. Neuroscience. 2003;122:689–698. [PubMed]
76. Zhou FC, Anthony B, Dunn KW, Lindquist WB, Xu ZC, Deng P. Chronic alcohol drinking alters neuronal dendritic spines in the brain reward center nucleus accumbens. Brain Res. 2007;1134:148–161. [PMC free article] [PubMed]
77. Raeder H, Holter SM, Hartmann AM, Spanagel R, Moller HJ, Rujescu D. Expression of N-methyl-d-aspartate (NMDA) receptor subunits and splice variants in an animal model of long-term voluntary alcohol self-administration. Drug Alcohol Depend. 2008;96:16–21. [PubMed]
78. Lobo IA, Harris RA. GABA(A) receptors and alcohol. Pharmacol Biochem Behav. 2008;90:90–94. [PMC free article] [PubMed]
79. Morrow AL, Montpied P, Lingford-Hughes A, Paul SM. Chronic ethanol and pentobarbital administration in the rat: effects on GABAA receptor function and expression in brain. Alcohol. 1990;7:237–244. [PubMed]
80. Wan FJ, Berton F, Madamba SG, Francesconi W, Siggins GR. Low ethanol concentrations enhance GABAergic inhibitory postsynaptic potentials in hippocampal pyramidal neurons only after block of GABAB receptors. Proc. Natl. Acad. Sci. U.S.A. 1996;93:5049–5054. [PubMed]
81. Kumar S, Porcu P, Werner DF, Matthews DB, Diaz-Granados JL, Helfand RS, Morrow AL. The role of GABA(A) receptors in the acute and chronic effects of ethanol: a decade of progress. Psychopharmacology (Berl) 2009;205:529–564. [PMC free article] [PubMed]
82. Mihic SJ, Ye Q, Wick MJ, Koltchine VV, Krasowski MD, Finn SE, Mascia MP, Valenzuela CF, Hanson KK, Greenblatt EP, Harris RA, Harrison NL. Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. Nature. 1997;389:385–389. [PubMed]
83. Mascia MP, Trudell JR, Harris RA. Specific binding sites for alcohols and anesthetics on ligand-gated ion channels. Proc. Natl. Acad. Sci. U.S.A. 2000;97:9305–9310. [PubMed]
84. Jung S, Harris RA. Sites in TM2 and 3 are critical for alcohol-induced conformational changes in GABA receptors. J. Neurochem. 2006;96:885–892. [PubMed]
85. Gallegos RA, Lee RS, Criado JR, Henriksen SJ, Steffensen SC. Adaptive responses of gamma-aminobutyric acid neurons in the ventral tegmental area to chronic ethanol. J. Pharmacol. Exp. Ther. 1999;291:1045–1053. [PubMed]
86. Xiao C, Ye JH. Ethanol dually modulates GABAergic synaptic transmission onto dopaminergic neurons in ventral tegmental area: role of mu-opioid receptors. Neuroscience. 2008;153:240–248. [PMC free article] [PubMed]
87. Margolis EB, Fields HL, Hjelmstad GO, Mitchell JM. Delta-opioid receptor expression in the ventral tegmental area protects against elevated alcohol consumption. J. Neurosci. 2008;28:12672–12681. [PubMed]
88. Michels G, Moss SJ. GABAA receptors: properties and trafficking. Crit. Rev. Biochem. Mol. Biol. 2007;42:3–14. [PubMed]
89. Boyle AE, Segal R, Smith BR, Amit Z. Bidirectional effects of GABAergic agonists and antagonists on maintenance of voluntary ethanol intake in rats. Pharmacol. Biochem. Behav. 1993;46:179–182. [PubMed]
90. Nowak KL, McBride WJ, Lumeng L, Li TK, Murphy JM. Blocking GABA(A) receptors in the anterior ventral tegmental area attenuates ethanol intake of the alcohol-preferring P rat. Psychopharmacology (Berl) 1998;139:108–116. [PubMed]
91. Tomkins DM, Fletcher PJ. Evidence that GABA(A) but not GABA(B) receptor activation in the dorsal raphe nucleus modulates ethanol intake in Wistar rats. Behav. Pharmacol. 1996;7:85–93. [PubMed]
92. Tian H, Chen HJ, Cross TH, Edenberg HJ. Alternative splicing and promoter use in the human GABRA2 gene. Brain Res. Mol. Brain Res. 2005;137:174–183. [PubMed]
93. Enoch MA. The role of GABA(A) receptors in the development of alcoholism. Pharmacol. Biochem. Behav. 2008;90:95–104. [PMC free article] [PubMed]
94. Edenberg HJ, Dick DM, Xuei X, Tian H, Almasy L, Bauer LO, Crowe RR, Goate A, Hesselbrock V, Jones K, Kwon J, Li TK, Nurnberger JI, Jr, O'Connor SJ, Reich T, Rice J, Schuckit MA, Porjesz B, Foroud T, Begleiter H. Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. Am. J. Hum. Genet. 2004;74:705–714. [PubMed]
95. Petrie J, Sapp DW, Tyndale RF, Park MK, Fanselow M, Olsen RW. Altered gabaa receptor subunit and splice variant expression in rats treated with chronic intermittent ethanol. Alcohol Clin. Exp. Res. 2001;25:819–828. [PubMed]
96. Krishek BJ, Xie X, Blackstone C, Huganir RL, Moss SJ, Smart TG. Regulation of GABAA receptor function by protein kinase C phosphorylation. Neuron. 1994;12:1081–1095. [PubMed]
97. Wafford KA, Burnett DM, Leidenheimer NJ, Burt DR, Wang JB, Kofuji P, Dunwiddie TV, Harris RA, Sikela JM. Ethanol sensitivity of the GABAA receptor expressed in Xenopus oocytes requires 8 amino acids contained in the gamma 2L subunit. Neuron. 1991;7:27–33. [PubMed]
98. Benkwitz C, Banks MI, Pearce RA. Influence of GABAA receptor gamma2 splice variants on receptor kinetics and isoflurane modulation. Anesthesiology. 2004;101:924–936. [PubMed]
99. Homanics GE, Harrison NL, Quinlan JJ, Krasowski MD, Rick CE, de Blas AL, Mehta AK, Kist F, Mihalek RM, Aul JJ, Firestone LL. Normal electrophysiological and behavioral responses to ethanol in mice lacking the long splice variant of the gamma2 subunit of the gamma-aminobutyrate type A receptor. Neuropharmacology. 1999;38:253–265. [PMC free article] [PubMed]
100. Meier J, Grantyn R. Preferential accumulation of GABAA receptor gamma 2L, not gamma 2S, cytoplasmic loops at rat spinal cord inhibitory synapses. J. Physiol. 2004;559:355–365. [PubMed]
101. Roberts AA, Kellogg CK. Synchronous postnatal increase in alpha1 and gamma2L GABA(A) receptor mRNAs and high affinity zolpidem binding across three regions of rat brain. Brain Res. Dev. Brain Res. 2000;119:21–32. [PubMed]
102. Solem M, McMahon T, Messing RO. Protein kinase A regulates regulates inhibition of N- and P/Q-type calcium channels by ethanol in PC12 cells. J. Pharmacol. Exp. Ther. 1997;282:1487–1495. [PubMed]
103. McMahon T, Andersen R, Metten P, Crabbe JC, Messing RO. Protein kinase C epsilon mediates up-regulation of N-type calcium channels by ethanol. Mol. Pharmacol. 2000;57:53–58. [PubMed]
104. Newton PM, Orr CJ, Wallace MJ, Kim C, Shin HS, Messing RO. Deletion of N-type calcium channels alters ethanol reward and reduces ethanol consumption in mice. J. Neurosci. 2004;24:9862–9869. [PubMed]
105. Newton PM, Zeng L, Wang V, Connolly J, Wallace MJ, Kim C, Shin HS, Belardetti F, Snutch TP, Messing RO. A Blocker of N- and T-type Voltage-Gated Calcium Channels Attenuates Ethanol-Induced Intoxication, Place Preference, Self-Administration, and Reinstatement. J. Neurosci. 2008;28:11712–11719. [PMC free article] [PubMed]
106. Lin Z, Harris C, Lipscombe D. The molecular identity of Ca channel alpha 1-subunits expressed in rat sympathetic neurons. J. Mol. Neurosci. 1996;7:257–267. [PubMed]
107. Lin Z, Haus S, Edgerton J, Lipscombe D. Identification of functionally distinct isoforms of the N-type Ca2+ channel in rat sympathetic ganglia and brain. Neuron. 1997;18:153–166. [PubMed]
108. Newton PM, Tully K, McMahon T, Connolly J, Dadgar J, Treistman SN, Messing RO. Chronic ethanol exposure induces an N-type calcium channel splice variant with altered channel kinetics. FEBS Lett. 2005;579:671–676. [PubMed]
109. Wang X, Wang G, Lemos JR, Treistman SN. Ethanol directly modulates gating of a dihydropyridine-sensitive Ca2+ channel in neurohypophysial terminals. J. Neurosci. 1994;14:5453–5460. [PubMed]
110. Grant AJ, Koski G, Treistman SN. Effect of chronic ethanol on calcium currents and calcium uptake in undifferentiated PC12 cells. Brain Res. 1993;600:280–284. [PubMed]
111. Little HJ, Dolin SJ, Halsey MJ. Calcium channel antagonists decrease the ethanol withdrawal syndrome. Life Sci. 1986;39:2059–2065. [PubMed]
112. Rezvani AH, Janowsky DS. Decreased alcohol consumption by verapamil in alcohol preferring rats. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1990;14:623–631. [PubMed]
113. Snutch TP, Tomlinson WJ, Leonard JP, Gilbert MM. Distinct calcium channels are generated by alternative splicing and are differentially expressed in the mammalian CNS. Neuron. 1991;7:45–57. [PubMed]
114. Walter HJ, McMahon T, Dadgar J, Wang D, Messing RO. Ethanol regulates calcium channel subunits by protein kinase C delta -dependent and -independent mechanisms. J. Biol. Chem. 2000;275:25717–25722. [PubMed]
115. Sah P, Faber ES. Channels underlying neuronal calcium-activated potassium currents. Prog. Neurobiol. 2002;66:345–353. [PubMed]
116. Cui J, Yang H, Lee US. Molecular mechanisms of BK channel activation. Cell Mol. Life Sci. 2009;66:852–875. [PMC free article] [PubMed]
117. Dopico AM, Lemos JR, Treistman SN. Ethanol increases the activity of large conductance, Ca(2+)-activated K+ channels in isolated neurohypophysial terminals. Mol. Pharmacol. 1996;49:40–48. [PubMed]
118. Pietrzykowski AZ, Martin GE, Puig SI, Knott TK, Lemos JR, Treistman SN. Alcohol tolerance in large-conductance, calcium-activated potassium channels of CNS terminals is intrinsic and includes two components: decreased ethanol potentiation and decreased channel density. J. Neurosci. 2004;24:8322–8332. [PubMed]
119. Jakab M, Weiger TM, Hermann A. Ethanol activates maxi Ca2+-activated K+ channels of clonal pituitary (GH3) cells. J. Membr. Biol. 1997;157:237–245. [PubMed]
120. Gruss M, Henrich M, Konig P, Hempelmann G, Vogel W, Scholz A. Ethanol reduces excitability in a subgroup of primary sensory neurons by activation of BK(Ca) channels. Eur. J. Neurosci. 2001;14:1246–1256. [PubMed]
121. Dopico AM. Ethanol sensitivity of BK(Ca) channels from arterial smooth muscle does not require the presence of the beta 1-subunit. Am. J. Physiol. Cell Physiol. 2003;284:C1468–1480. [PubMed]
122. Walters FS, Covarrubias M, Ellingson JS. Potent inhibition of the aortic smooth muscle maxi-K channel by clinical doses of ethanol. Am. J. Physiol. Cell Physiol. 2000;279:C1107–1115. [PubMed]
123. Martin G, Puig S, Pietrzykowski A, Zadek P, Emery P, Treistman S. Somatic localization of a specific large-conductance calcium-activated potassium channel subtype controls compartmentalized ethanol sensitivity in the nucleus accumbens. J. Neurosci. 2004;24:6563–6572. [PubMed]
124. Liu J, Asuncion-Chin M, Liu P, Dopico AM. CaM kinase II phosphorylation of slo Thr107 regulates activity and ethanol responses of BK channels. Nat. Neurosci. 2006;9:41–49. [PMC free article] [PubMed]
125. Crowley JJ, Treistman SN, Dopico AM. Cholesterol antagonizes ethanol potentiation of human brain BKCa channels reconstituted into phospholipid bilayers. Mol. Pharmacol. 2003;64:365–372. [PubMed]
126. Crowley JJ, Treistman SN, Dopico AM. Distinct structural features of phospholipids differentially determine ethanol sensitivity and basal function of BK channels. Mol. Pharmacol. 2005;68:4–10. [PubMed]
127. Yuan C, O'Connell RJ, Wilson A, Pietrzykowski AZ, Treistman SN. Acute alcohol tolerance is intrinsic to the BKCa protein, but is modulated by the lipid environment. J. Biol. Chem. 2008;283:5090–5098. [PubMed]
128. Martin GE, Hendrickson LM, Penta KL, Friesen RM, Pietrzykowski AZ, Tapper AR, Treistman SN. Identification of a BK channel auxiliary protein controlling molecular and behavioral tolerance to alcohol. Proc. Natl. Acad. Sci. U.S.A. 2008;105:17543–17548. [PubMed]
129. Pietrzykowski AZ, Friesen RM, Martin GE, Puig SI, Nowak CL, Wynne PM, Siegelmann HT, Treistman SN. Posttranscriptional regulation of BK channel splice variant stability by miR-9 underlies neuroadaptation to alcohol. Neuron. 2008;59:274–287. [PMC free article] [PubMed]
130. Charness ME, Safran RM, Perides G. Ethanol inhibits neural cell-cell adhesion. J. Biol. Chem. 1994;269:9304–9309. [PubMed]
131. Bearer CF, Swick AR, O'Riordan MA, Cheng G. Ethanol inhibits L1-mediated neurite outgrowth in postnatal rat cerebellar granule cells. J. Biol. Chem. 1999;274:13264–13270. [PubMed]
132. Arevalo E, Shanmugasundararaj S, Wilkemeyer MF, Dou X, Chen S, Charness ME, Miller KW. An alcohol binding site on the neural cell adhesion molecule L1. Proc. Natl. Acad. Sci. U.S.A. 2008;105:371–375. [PubMed]
133. Yeaney NK, He M, Tang N, Malouf AT, O'Riordan MA, Lemmon V, Bearer CF. Ethanol inhibits L1 cell adhesion molecule tyrosine phosphorylation and dephosphorylation and activation of pp60(src) J. Neurochem. 2009;110:779–790. [PMC free article] [PubMed]
134. Craig AM, Kang Y. Neurexin-neuroligin signaling in synapse development. Curr. Opin. Neurobiol. 2007;17:43–52. [PMC free article] [PubMed]
135. Graf ER, Zhang X, Jin SX, Linhoff MW, Craig AM. Neurexins induce differentiation of GABA and glutamate postsynaptic specializations via neuroligins. Cell. 2004;119:1013–1026. [PMC free article] [PubMed]
136. Missler M, Zhang W, Rohlmann A, Kattenstroth G, Hammer RE, Gottmann K, Shof TC. Alpha-neurexins couple Ca2+ channels to synaptic vesicle exocytosis. Nature. 2003;423:939–948. [PubMed]
137. Zhang W, Rohlmann A, Sargsyan V, Aramuni G, Hammer RE, Shof TC, Missler M. Extracellular domains of alpha-neurexins participate in regulating synaptic transmission by selectively affecting N- and P/Q-type Ca2+ channels. J. Neurosci. 2005;25:4330–4342. [PubMed]
138. Dudanova I, Sedej S, Ahmad M, Masius H, Sargsyan V, Zhang W, Riedel D, Angenstein F, Schild D, Rupnik M, Missler M. Important contribution of alpha-neurexins to Ca2+-triggered exocytosis of secretory granules. J. Neurosci. 2006;26:10599–10613. [PubMed]
139. Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF, Swan GE, Rutter J, Bertelsen S, Fox L, Fugman D, Goate AM, Hinrichs AL, Konvicka K, Martin NG, Montgomery GW, Saccone NL, Saccone SF, Wang JC, Chase GA, Rice JP, Ballinger DG. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum. Mol. Genet. 2007;16:24–35. [PMC free article] [PubMed]
140. Nussbaum J, Xu Q, Payne TJ, Ma JZ, Huang W, Gelernter J, Li MD. Significant association of the neurexin-1 gene (NRXN1) with nicotine dependence in European- and African-American smokers. Hum. Mol. Genet. 2008;17:1569–1577. [PMC free article] [PubMed]
141. Lachman HM, Fann CS, Bartzis M, Evgrafov OV, Rosenthal RN, Nunes EV, Miner C, Santana M, Gaffney J, Riddick A, Hsu CL, Knowles JA. Genomewide suggestive linkage of opioid dependence to chromosome 14q. Hum. Mol. Genet. 2007;16:1327–1334. [PubMed]
142. Liu QR, Drgon T, Walther D, Johnson C, Poleskaya O, Hess J, Uhl GR. Pooled association genome scanning: validation and use to identify addiction vulnerability loci in two samples. Proc. Natl. Acad. Sci. U.S.A. 2005;102:11864–11869. [PubMed]
143. Kelai S, Maussion G, Noble F, Boni C, Ramoz N, Moalic JM, Peuchmaur M, Gorwood P, Simonneau M. Nrxn3 upregulation in the globus pallidus of mice developing cocaine addiction. Neuroreport. 2008;19:751–755. [PubMed]
144. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, Boguski MS, Brockway KS, Byrnes EJ, Chen L, Chen TM, Chin MC, Chong J, Crook BE, Czaplinska A, Dang CN, Datta S, Dee NR, Desaki AL, Desta T, Diep E, Dolbeare TA, Donelan MJ, Dong HW, Dougherty JG, Duncan BJ, Ebbert AJ, Eichele G, Estin LK, Faber C, Facer BA, Fields R, Fischer SR, Fliss TP, Frensley C, Gates SN, Glattfelder KJ, Halverson KR, Hart MR, Hohmann JG, Howell MP, Jeung DP, Johnson RA, Karr PT, Kawal R, Kidney JM, Knapik RH, Kuan CL, Lake JH, Laramee AR, Larsen KD, Lau C, Lemon TA, Liang AJ, Liu Y, Luong LT, Michaels J, Morgan JJ, Morgan RJ, Mortrud MT, Mosqueda NF, Ng LL, Ng R, Orta GJ, Overly CC, Pak TH, Parry SE, Pathak SD, Pearson OC, Puchalski RB, Riley ZL, Rockett HR, Rowland SA, Royall JJ, Ruiz MJ, Sarno NR, Schaffnit K, Shapovalova NV, Sivisay T, Slaughterbeck CR, Smith SC, Smith KA, Smith BI, Sodt AJ, Stewart NN, Stumpf KR, Sunkin SM, Sutram M, Tam A, Teemer CD, Thaller C, Thompson CL, Varnam LR, Visel A, Whitlock RM, Wohnoutka PE, Wolkey CK, Wong VY, Wood M, et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature. 2007;445:168–176. [PubMed]
145. Chih B, Gollan L, Scheiffele P. Alternative splicing controls selective trans-synaptic interactions of the neuroligin-neurexin complex. Neuron. 2006;51:171–178. [PubMed]
146. Boucard AA, Chubykin AA, Comoletti D, Taylor P, Shof TC. A splice code for trans-synaptic cell adhesion mediated by binding of neuroligin 1 to alpha- and beta-neurexins. Neuron. 2005;48:229–236. [PubMed]
147. Hishimoto A, Liu QR, Drgon T, Pletnikova O, Walther D, Zhu XG, Troncoso JC, Uhl GR. Neurexin 3 polymorphisms are associated with alcohol dependence and altered expression of specific isoforms. Hum. Mol. Genet. 2007;16:2880–2891. [PubMed]
148. Albano E. Alcohol, oxidative stress and free radical damage. Proc. Nutr. Soc. 2006;65:278–290. [PubMed]
149. Biamonti G, Caceres JF. Cellular stress and RNA splicing. Trends Biochem. Sci. 2009;34:146–153. [PubMed]
150. Castle JC, Zhang C, Shah JK, Kulkarni AV, Kalsotra A, Cooper TA, Johnson JM. Expression of 24,426 human alternative splicing events and predicted cis regulation in 48 tissues and cell lines. Nat. Genet. 2008;40:1416–1425. [PMC free article] [PubMed]

Articles from International Journal of Environmental Research and Public Health are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)